Lineage Cell Therapeutics Inc Share Price Today: Live Updates & Key Insights
Lineage Cell Therapeutics Inc share price today is $1.45, up -6.45%. The stock opened at $1.55 against the previous close of $1.55, with an intraday high of $1.55 and low of $1.445.
Lineage Cell Therapeutics Inc Share Price Chart
Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics Inc Share Price Performance
Lineage Cell Therapeutics Inc Institutional Holdings
Lineage Cell Therapeutics Inc Market Status
Lineage Cell Therapeutics Inc Fundamentals
Market Cap 361.18 M
PB Ratio 8.1074
PE Ratio 0.0
Enterprise Value 307.81 M
Total Assets 112.58 M
Volume 1447900
Lineage Cell Therapeutics Inc Company Financials
About Lineage Cell Therapeutics Inc & investment objective
Company Information Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Organisation Biotechnology
Employees 72
Industry Biotechnology
CEO Mr. Brian M. Culley M.A., M.B.A.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:
Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*
Take your next step
Lineage Cell Therapeutics Inc FAQs
What is the share price of Lineage Cell Therapeutics Inc today?
The current share price of Lineage Cell Therapeutics Inc is $1.45.
Can I buy Lineage Cell Therapeutics Inc shares in India?
Yes, Indian investors can buy Lineage Cell Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.
How to buy Lineage Cell Therapeutics Inc shares in India?
You can easily invest in Lineage Cell Therapeutics Inc shares from India by:
- Direct Investment:
Opening an international trading account with Motilal Oswal which includes KYC verification in the US. Your account gets activated in a few minutes to a few hours, after which you can start adding funds in USD balance to buy Lineage Cell Therapeutics Inc shares. - Indirect Investment:
Under this form of investment, you can choose either a Mutual Fund (MF) or an Exchange-Traded Fund (ETF) that invests in global shares and start investing in shares of Lineage Cell Therapeutics Inc.
Can I buy fractional shares of Lineage Cell Therapeutics Inc?
Yes, many platforms allow you to buy fractional shares starting from as low as $1.
What is the market capitalization value of Lineage Cell Therapeutics Inc?
Lineage Cell Therapeutics Inc has a market cap of $361.18 M.
In which sector does Lineage Cell Therapeutics Inc belong?
Lineage Cell Therapeutics Inc operates in the Biotechnology sector.
What documents are required to invest in Lineage Cell Therapeutics Inc stocks?
To invest, you typically need:
What is the PE and PB ratio of Lineage Cell Therapeutics Inc?
The PE ratio of Lineage Cell Therapeutics Inc is N/A and the PB ratio is 8.11.